20.06.2024 14:55:03 - dpa-AFX: *GILEAD'S LENACAPAVIR SHOWS 100% EFFICACY IN HIV PREVENTION FOR CISGENDER WOMEN IN PHASE 3 TRIAL

Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
Gilead Sciences 885823 NASDAQ 74,750 20.08.24 22:00:04 +0,300 +0,40% 74,750 74,900 74,540 74,450

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH